'Only get a couple of shots': VCs back Eucalyptus strategy as it nears $1b milestone
On the cusp of becoming Australia's next unicorn, Euc has parted ways with senior staff and paused a product expansion to focus on its core business. Investors say that's a good thing.
Venture capital investors in heavily hyped healthcare play Eucalyptus have endorsed its move to retreat from an expansion into men's longevity and instead focus on its booming weight loss business as it finalises a funding round expected to value it at more than $1 billion.
As Capital Brief revealed last week Eucalyptus executive Dan Cable recently left the business as Compound, the longevity product he led, was delayed in the UK after already being paused in Australia.
Compound targets men who are seeking a healthier lifestyle by offering medication such as GLP-1s, along with supplements, strength routines, gym discounts and group coaching. The Australian version of the program charged $1,000 a month.
Airtree general partner Jackie Vullinghs said the VC supported the move as Eucalyptus was growing “incredibly fast” and at scale through its GLP-1 offerings — a class of drugs used commonly for weight loss.
